About Casebia

Scaled for Success

Pioneering a new field of medicine requires more than vision. It takes a long-term commitment, sufficient resources and a collaborative approach to seize on the emerging breakthroughs that will define the future.

Casebia Therapeutics, a 50-50 joint venture between CRISPR Therapeutics and Bayer, was created to accelerate the field of gene editing therapeutics today, and for the long haul. Drawing on CRISPR/Cas9 technology and expertise from CRISPR Therapeutics and the distinctive disease know-how and protein engineering capabilities of Bayer, we are working to redefine what’s possible for patients with a wide range of inherited diseases.

Read more read more